<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01485692</url>
  </required_header>
  <id_info>
    <org_study_id>UE0001</org_study_id>
    <nct_id>NCT01485692</nct_id>
  </id_info>
  <brief_title>Four Interventions in the Management of Psychomotor Agitation, Safety and Efficacy Evaluation</brief_title>
  <official_title>Safety and Efficacy of Four Intramuscular Interventions for the Management of Acute Psychomotor Agitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to evaluate the efficacy and safety of four options of medications in the
      management of acute psychomotor agitation,or violence and aggression situations in health
      services. All of the treatment options are already approved and currently used for this
      purpose. The options are: haloperidol plus midazolam, haloperidol plus promethazine,
      olanzapine and ziprasidone. The investigators hypothesized that all treatment options are
      effective in the treatment of acute agitation, but the combination haloperidol plus
      promethazine could elicit more adverse affects than the others.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in the agitation score</measure>
    <time_frame>90 minutes</time_frame>
    <description>Agitation scores were evaluated through two previously validated specific scales: ACES ( Agitation Calmness Evaluating Scale) and PANSS-EC ( Positive and Negative Symptoms Scale- Excited Component). The measure was collected by a blind rater at baseline and the subsequent measures aimed to evaluate the drug effect over agitation scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse effects</measure>
    <time_frame>12,24 hours after baseline</time_frame>
    <description>Aiming to evaluate the occurrence of adverse effects in the 24 hours period of observation after administrating the first injection (Baseline), an exert from the UKU scale (Ugvalg klinisk Undersgelser Side Effect Scale )was applied by a blind rater, to evaluate the presence and intensity of possible side effects.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Psychomotor Agitation</condition>
  <arm_group>
    <arm_group_label>ziprasidone injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ziprasidone injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of the observation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>haloperidol + midazolam, injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Haloperidol plus midazolam injection, after baseline measures of agitation,allowed to be repeated twice over the 90 minutes period of observation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>haloperidol + promethazine, injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>haloperidol + promethazine injection after baseline measures of agitation, could be repeated after 30 minutes, and once more, if necessary, in the 90 minutes period of observation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>olanzapine, injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>olanzapine, 10mg, intramuscular injection after baseline measures of agitation, could be repeated twice if necessary, between the 90 minutes of observation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>haloperidol+promethazine</intervention_name>
    <description>haloperidol, 2,5mg plus promethazine,25mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, in the 90 minutes period of observation</description>
    <arm_group_label>haloperidol + promethazine, injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>haloperidol + midazolam</intervention_name>
    <description>haloperidol, 2,5mg plus midazolam, 7,5 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation</description>
    <arm_group_label>haloperidol + midazolam, injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olanzapine</intervention_name>
    <description>olanzapine, 10mg, intramuscular injection, after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of observation</description>
    <arm_group_label>olanzapine, injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone</intervention_name>
    <description>ziprasidone, 10 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation</description>
    <arm_group_label>ziprasidone injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients featuring psychomotor agitation, with clinical need for intramuscular
             injection

        Exclusion Criteria:

          -  delirium, severe or unstable general medical condition, previous history of severe
             adverse effects with one of the treatment options
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Celia Mantovani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sao Paulo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina de Ribeirão Preto, USP</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>São Paulo</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2011</study_first_submitted>
  <study_first_submitted_qc>December 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2011</study_first_posted>
  <last_update_submitted>December 1, 2011</last_update_submitted>
  <last_update_submitted_qc>December 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Celia Mantovani</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Violence</keyword>
  <keyword>Aggression</keyword>
  <keyword>Psychiatric emergencies</keyword>
  <keyword>Psychomotor agitation</keyword>
  <keyword>Violent patient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Ziprasidone</mesh_term>
    <mesh_term>Promethazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

